These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33234652)

  • 21. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
    Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
    BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study.
    Collins M; Mason H; O'Flaherty M; Guzman-Castillo M; Critchley J; Capewell S
    Value Health; 2014 Jul; 17(5):517-24. PubMed ID: 25128044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
    Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
    Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of simulation models in health economic evaluation studies of dietary salt-reduction policies for cardiovascular disease prevention].
    Kato H; Ikeda N; Sugiyama T; Nomura M; Yoshita K; Nishi N
    Nihon Koshu Eisei Zasshi; 2021 Sep; 68(9):631-643. PubMed ID: 34261839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of LiveLighter® - a mass media public education campaign for obesity prevention.
    Ananthapavan J; Tran HNQ; Morley B; Hart E; Kennington K; Stevens-Cutler J; Bowe SJ; Crosland P; Moodie M
    PLoS One; 2022; 17(9):e0274917. PubMed ID: 36129952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of government actions to reduce sodium intake through salt substitutes in Vietnam.
    Taylor C; Hoek AC; Deltetto I; Peacock A; Ha DTP; Sieburg M; Hoang D; Trieu K; Cobb LK; Jan S; Webster J
    Arch Public Health; 2021 Mar; 79(1):32. PubMed ID: 33706807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
    Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
    PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The health, cost and equity impacts of restrictions on the advertisement of high fat, salt and sugar products across the transport for London network: a health economic modelling study.
    Thomas C; Breeze P; Cummins S; Cornelsen L; Yau A; Brennan A
    Int J Behav Nutr Phys Act; 2022 Jul; 19(1):93. PubMed ID: 35897072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women.
    Brand A; Visser ME; Schoonees A; Naude CE
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015207. PubMed ID: 35944931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The health and economic impact and cost effectiveness of interventions for the prevention and control of overweight and obesity in Kenya: a stakeholder engaged modelling study.
    Wanjau MN; Kivuti-Bitok LW; Aminde LN; Veerman JL
    Cost Eff Resour Alloc; 2023 Sep; 21(1):69. PubMed ID: 37735408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling health gains and cost savings for ten dietary salt reduction targets.
    Wilson N; Nghiem N; Eyles H; Mhurchu CN; Shields E; Cobiac LJ; Cleghorn CL; Blakely T
    Nutr J; 2016 Apr; 15():44. PubMed ID: 27118548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations.
    Webb M; Fahimi S; Singh GM; Khatibzadeh S; Micha R; Powles J; Mozaffarian D
    BMJ; 2017 Jan; 356():i6699. PubMed ID: 28073749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
    Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population.
    Dodhia H; Phillips K; Zannou MI; Airoldi M; Bevan G
    J Hypertens; 2012 Jan; 30(1):217-26. PubMed ID: 22080224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK.
    Kypridemos C; Collins B; McHale P; Bromley H; Parvulescu P; Capewell S; O'Flaherty M
    PLoS Med; 2018 May; 15(5):e1002573. PubMed ID: 29813056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.